TheraVectys, a French biotechnology company, plans to go public in Hong Kong, which may break industry norms

TheraVectys SA is considering an initial public offering (IPO) in Hong Kong, which could take place as early as this year. This move is relatively rare among biotech companies outside of China, as they typically choose to list in European and American markets. If successful, it will break the industry norm and reflect China's rise in the field of innovation and the attractiveness of the Hong Kong market. TheraVectys primarily develops lentiviral vectors, with investors including Tethys Invest SAS